Genetron Holdings Key Executives
This section highlights Genetron Holdings's key executives, including their titles and compensation details.
Find Contacts at Genetron Holdings
(Showing 0 of )
Genetron Holdings Earnings
This section highlights Genetron Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
$4.03
Stock Price
$127.29M
Market Cap
100.00K
Employees
Beijing, None
Location
Financial Statements
Access annual & quarterly financial statements for Genetron Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $650.71M | $531.95M | $424.49M | $323.43M | $225.18M |
| Cost of Revenue | $369.28M | $193.98M | $164.27M | $178.44M | $132.45M |
| Gross Profit | $281.43M | $337.97M | $260.22M | $144.99M | $92.73M |
| Gross Profit Ratio | 43.25% | 63.50% | 61.30% | 44.83% | 41.18% |
| Research and Development Expenses | $290.29M | $253.95M | $149.00M | $91.70M | $71.41M |
| General and Administrative Expenses | $266.91M | $227.00M | $126.32M | $117.17M | $88.23M |
| Selling and Marketing Expenses | $364.56M | $343.16M | $246.96M | $253.56M | $182.47M |
| Selling General and Administrative Expenses | $631.47M | $570.16M | $373.28M | $370.73M | $270.71M |
| Other Expenses | $-8.71M | $-5.33M | $-8.53M | $-10.85M | $-233.63M |
| Operating Expenses | $913.05M | $818.78M | $513.75M | $451.58M | $332.19M |
| Cost and Expenses | $1.28B | $1.01B | $678.02M | $630.01M | $464.64M |
| Interest Income | $2.86M | $20.50M | $28.33M | $441.00K | $1.55M |
| Interest Expense | $111.48M | $5.25M | $5.63M | $5.40M | $- |
| Depreciation and Amortization | $85.39M | $20.50M | $-2.80B | $-319.22M | $27.86M |
| EBITDA | $-651.24M | $-460.31M | $-201.69M | $-625.81M | $-212.21M |
| EBITDA Ratio | -83.94% | -86.53% | -718.18% | -193.49% | -197.04% |
| Operating Income | $-631.62M | $-480.82M | $-253.53M | $-306.59M | $-232.98M |
| Operating Income Ratio | -97.07% | -90.39% | -59.73% | -94.79% | -103.46% |
| Total Other Income Expenses Net | $-108.69M | $21.04M | $-2.80B | $-366.94M | $-225.53M |
| Income Before Tax | $-810.63M | $-502.60M | $-3.07B | $-676.03M | $-464.99M |
| Income Before Tax Ratio | -124.58% | -94.48% | -723.00% | -209.02% | -206.50% |
| Income Tax Expense | $73.26M | $-64.19M | $-2.87B | $-354.54M | $-232.02M |
| Net Income | $-883.89M | $-438.40M | $-198.10M | $-321.49M | $-464.99M |
| Net Income Ratio | -135.84% | -82.41% | -46.67% | -99.40% | -206.50% |
| EPS | $-9.53 | $-4.76 | $-3.29 | $-4.65 | $-6.73 |
| EPS Diluted | $-9.53 | $-4.76 | $-3.29 | $-4.65 | $-6.73 |
| Weighted Average Shares Outstanding | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M |
| Weighted Average Shares Outstanding Diluted | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.32M | $201.32M | $137.75M | $110.32M | $146.86M | $152.54M | $140.49M | $92.06M | $133.94M | $111.96M | $101.73M | $76.84M | $102.94M | $81.34M | $72.49M | $66.65M | $73.98M |
| Cost of Revenue | $119.39M | $119.39M | $81.66M | $48.85M | $63.14M | $47.31M | $46.02M | $37.51M | $49.82M | $42.33M | $37.51M | $34.60M | $57.12M | $45.40M | $37.83M | $38.09M | $42.35M |
| Gross Profit | $81.93M | $81.93M | $56.09M | $61.47M | $83.72M | $105.23M | $94.46M | $54.55M | $84.12M | $69.63M | $64.22M | $42.24M | $45.82M | $35.95M | $34.66M | $28.57M | $31.63M |
| Gross Profit Ratio | 40.70% | 40.70% | 40.70% | 55.70% | 57.00% | 69.00% | 67.20% | 59.30% | 62.81% | 62.19% | 63.13% | 54.97% | 44.51% | 44.19% | 47.81% | 42.86% | 42.75% |
| Research and Development Expenses | $74.54M | $74.54M | $61.64M | $79.56M | $85.45M | $62.36M | $56.16M | $49.97M | $52.97M | $38.56M | $29.84M | $27.63M | $32.36M | $20.75M | $19.17M | $19.42M | $21.15M |
| General and Administrative Expenses | $78.27M | $78.27M | $60.14M | $50.24M | $64.84M | $62.98M | $54.58M | $44.60M | $44.35M | $32.44M | $27.91M | $21.62M | $28.70M | $33.42M | $27.85M | $27.21M | $30.92M |
| Selling and Marketing Expenses | $89.51M | $89.51M | $94.69M | $90.84M | $100.35M | $94.62M | $88.52M | $59.67M | $71.96M | $60.56M | $60.62M | $53.82M | $69.01M | $65.72M | $65.25M | $53.59M | $62.42M |
| Selling General and Administrative Expenses | $197.28M | $197.28M | $154.83M | $141.09M | $165.19M | $157.61M | $143.09M | $104.27M | $116.31M | $93.00M | $88.52M | $75.45M | $97.71M | $99.13M | $93.10M | $80.79M | $93.33M |
| Other Expenses | $- | $- | $989.00K | $7.61M | $3.62M | $-334.00K | $-8.08M | $- | $2.40M | $- | $-2.78B | $-44.78M | $-43.98M | $-187.96M | $-67.81M | $-60.19M | $-42.19M |
| Operating Expenses | $311.81M | $311.81M | $217.46M | $228.26M | $254.25M | $219.64M | $191.17M | $153.72M | $160.24M | $127.73M | $117.10M | $108.68M | $131.04M | $119.62M | $101.79M | $99.12M | $121.32M |
| Cost and Expenses | $431.19M | $431.19M | $299.12M | $277.11M | $317.40M | $266.94M | $237.19M | $191.23M | $210.06M | $170.07M | $154.61M | $143.28M | $188.16M | $165.02M | $139.62M | $137.21M | $163.68M |
| Interest Income | $30.10M | $30.10M | $541.00K | $5.90M | $18.79M | $482.00K | $9.45M | $105.00K | $17.27M | $12.77M | $198.00K | $30.00K | $3.00K | $26.00K | $84.00K | $328.00K | $624.00K |
| Interest Expense | $- | $- | $66.60M | $906.00K | $229.00K | $5.79M | $1.41M | $6.14M | $1.63M | $1.56M | $827.00K | $1.22M | $1.80M | $2.13M | $1.07M | $401.00K | $- |
| Depreciation and Amortization | $54.88K | $27.08K | $541.00K | $5.90M | $21.37M | $1.66M | $9.77M | $9.94M | $30.01M | $13.88M | $-2.78B | $-44.03M | $-50.74M | $-187.60M | $-67.97M | $-59.22M | $-48.38M |
| EBITDA | $-163.29M | $-166.75M | $-160.83M | $-160.89M | $-151.75M | $-113.92M | $-87.26M | $-99.06M | $-58.85M | $-45.33M | $-2.83B | $-111.19M | $-135.50M | $-271.61M | $-134.86M | $-130.43M | $-131.26M |
| EBITDA Ratio | -81.11% | -82.83% | -116.75% | -145.84% | -103.33% | -74.68% | -62.12% | -107.61% | -43.93% | -40.49% | -2782.98% | -144.70% | -131.63% | -333.90% | -186.04% | -195.68% | -177.42% |
| Operating Income | $-175.97M | $-175.97M | $-161.37M | $-166.79M | $-183.83M | $-124.84M | $-100.18M | $-109.00M | $-88.86M | $-59.21M | $-53.14M | $-67.16M | $-84.76M | $-84.01M | $-66.89M | $-71.21M | $-82.88M |
| Operating Income Ratio | -87.41% | -87.41% | -117.15% | -151.19% | -125.17% | -81.84% | -71.31% | -118.40% | -66.34% | -52.88% | -52.24% | -87.40% | -82.34% | -103.28% | -92.28% | -106.84% | -112.02% |
| Total Other Income Expenses Net | $-23.81M | $-23.81M | $-74.81M | $-8.11M | $24.35M | $-5.31M | $8.04M | $-6.04M | $17.28M | $11.21M | $-2.78B | $-48.30M | $-50.04M | $-190.06M | $-68.80M | $-60.27M | $-34.69M |
| Income Before Tax | $-199.78M | $-199.78M | $-236.18M | $-174.89M | $-165.27M | $-130.15M | $-92.15M | $-115.04M | $-73.22M | $-48.00M | $-2.83B | $-115.46M | $-134.80M | $-274.07M | $-135.69M | $-131.47M | $-124.38M |
| Income Before Tax Ratio | -99.24% | -99.24% | -171.46% | -158.53% | -112.53% | -85.32% | -65.59% | -124.96% | -54.67% | -42.87% | -2784.06% | -150.25% | -130.95% | -336.93% | -187.18% | -197.26% | -168.12% |
| Income Tax Expense | $-371.00K | $-371.00K | $-1.50M | $-6.42M | $-21.37M | $-1.17M | $-326.00K | $-3.79M | $-28.38M | $-12.32M | $362.00K | $463.00K | $8.55M | $1.78M | $1.23M | $-576.00K | $6.19M |
| Net Income | $-199.41M | $-199.41M | $-234.67M | $-168.47M | $-162.69M | $-128.97M | $-91.82M | $-115.04M | $-73.22M | $-48.00M | $-2.83B | $-115.46M | $-134.80M | $-274.07M | $-135.69M | $-131.47M | $-124.38M |
| Net Income Ratio | -99.05% | -99.05% | -170.36% | -152.71% | -110.78% | -84.55% | -65.36% | -124.96% | -54.67% | -42.87% | -2784.06% | -150.25% | -130.95% | -336.93% | -187.18% | -197.26% | -168.12% |
| EPS | $-6.44 | $-6.44 | $-2.53 | $-1.82 | $-1.76 | $-1.40 | $-1.00 | $-1.26 | $-0.83 | $-0.53 | $-85.22 | $-1.35 | $-1.95 | $-3.97 | $-1.96 | $-1.90 | $-1.80 |
| EPS Diluted | $-6.44 | $-6.44 | $-2.53 | $-1.82 | $-1.76 | $-1.40 | $-1.00 | $-1.26 | $-0.83 | $-0.53 | $-85.22 | $-1.35 | $-1.95 | $-3.97 | $-1.96 | $-1.90 | $-1.80 |
| Weighted Average Shares Outstanding | 30.98M | 30.98M | 92.72M | 92.57M | 92.56M | 92.27M | 91.98M | 91.62M | 88.36M | 90.85M | 33.24M | 85.36M | 69.07M | 69.07M | 69.07M | 69.07M | 69.07M |
| Weighted Average Shares Outstanding Diluted | 30.98M | 30.98M | 92.72M | 92.57M | 92.56M | 92.27M | 91.98M | 91.62M | 88.36M | 90.85M | 33.24M | 85.36M | 69.07M | 69.07M | 69.07M | 69.07M | 69.07M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $176.27M | $639.04M | $1.38B | $139.95M | $62.13M |
| Short Term Investments | $157.43M | $151.44M | $140.29M | $122.22M | $38.60M |
| Cash and Short Term Investments | $333.69M | $790.49M | $1.52B | $262.18M | $100.72M |
| Net Receivables | $323.36M | $388.38M | $208.34M | $105.37M | $70.86M |
| Inventory | $42.43M | $35.60M | $24.97M | $17.90M | $21.61M |
| Other Current Assets | $9.47M | $32.71M | $36.70M | $43.71M | $37.49M |
| Total Current Assets | $708.95M | $1.25B | $1.79B | $429.15M | $230.69M |
| Property Plant Equipment Net | $177.64M | $162.36M | $136.60M | $126.19M | $82.55M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $32.07M | $20.70M | $12.27M | $5.48M | $3.40M |
| Goodwill and Intangible Assets | $32.07M | $20.70M | $12.27M | $5.48M | $3.40M |
| Long Term Investments | $50.50M | $49.78M | $19.61M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.17M | $37.61M | $15.36M | $12.68M | $7.80M |
| Total Non-Current Assets | $266.37M | $270.44M | $183.83M | $144.36M | $93.75M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $975.33M | $1.52B | $1.97B | $573.51M | $324.44M |
| Account Payables | $63.05M | $55.77M | $34.07M | $49.95M | $11.90M |
| Short Term Debt | $131.22M | $40.13M | $75.17M | $34.88M | $929.00K |
| Tax Payables | $3.04M | $2.58M | $1.67M | $4.63M | $929.00K |
| Deferred Revenue | $22.04M | $11.96M | $8.42M | $18.19M | $8.87M |
| Other Current Liabilities | $170.52M | $154.65M | $109.52M | $105.08M | $54.02M |
| Total Current Liabilities | $389.87M | $265.09M | $228.84M | $212.74M | $67.77M |
| Long Term Debt | $27.34M | $33.87M | $48.51M | $32.77M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $9.76M | $8.61M | $-48.51M | $2.07B | $1.32B |
| Total Non-Current Liabilities | $37.10M | $42.48M | $48.51M | $2.14B | $1.32B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $426.97M | $307.57M | $277.35M | $2.35B | $1.39B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $61.00K | $61.00K | $59.00K | $17.00K | $- |
| Retained Earnings | $-6.25B | $-5.44B | $-4.94B | $-1.84B | $-1.17B |
| Accumulated Other Comprehensive Income Loss | $56.17M | $-69.09M | $-24.70M | $69.21M | $112.26M |
| Other Total Stockholders Equity | $6.79B | $6.64B | $6.63B | $-3.58M | $-8.36M |
| Total Stockholders Equity | $546.12M | $1.21B | $1.69B | $-1.78B | $-1.06B |
| Total Equity | $548.36M | $1.21B | $1.69B | $-1.78B | $-1.06B |
| Total Liabilities and Stockholders Equity | $975.33M | $1.52B | $1.97B | $573.51M | $324.44M |
| Minority Interest | $2.23M | $4.46M | $- | $- | $- |
| Total Liabilities and Total Equity | $975.33M | $1.52B | $1.97B | $573.51M | $324.44M |
| Total Investments | $207.92M | $201.22M | $159.90M | $122.22M | $38.60M |
| Total Debt | $158.57M | $73.99M | $123.68M | $67.64M | $- |
| Net Debt | $-17.70M | $-565.05M | $-1.25B | $-72.31M | $-62.13M |
Balance Sheet Charts
| Breakdown | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $176.27M | $176.27M | $327.55M | $319.29M | $639.04M | $815.14M | $1.07B | $1.07B | $1.38B | $1.64B | $1.84B | $180.89M | $139.95M | $5.39M | $62.13M |
| Short Term Investments | $5.17M | $5.17M | $145.13M | $239.82M | $151.44M | $187.40M | $142.19M | $318.61M | $140.29M | $233.53M | $47.72M | $103.02M | $122.22M | $- | $38.60M |
| Cash and Short Term Investments | $338.86M | $338.86M | $472.68M | $559.11M | $790.49M | $1.00B | $1.21B | $1.39B | $1.52B | $1.87B | $1.89B | $283.91M | $262.18M | $5.39M | $100.72M |
| Net Receivables | $257.93M | $257.93M | $432.18M | $406.56M | $388.38M | $365.58M | $261.15M | $224.10M | $208.34M | $162.79M | $115.20M | $114.77M | $105.37M | $59.98M | $70.86M |
| Inventory | $82.73M | $82.73M | $55.02M | $42.99M | $35.60M | $41.66M | $32.98M | $25.96M | $24.97M | $22.97M | $18.19M | $24.66M | $17.90M | $18.17M | $21.61M |
| Other Current Assets | $29.43M | $29.43M | $29.89M | $35.76M | $32.71M | $29.99M | $37.00M | $38.88M | $36.70M | $40.49M | $39.70M | $43.82M | $43.71M | $68.42M | $37.49M |
| Total Current Assets | $708.95M | $708.95M | $989.76M | $1.04B | $1.25B | $1.44B | $1.54B | $1.68B | $1.79B | $2.09B | $2.06B | $467.15M | $429.15M | $151.97M | $230.69M |
| Property Plant Equipment Net | $177.64M | $177.64M | $205.05M | $179.62M | $162.36M | $136.38M | $132.33M | $134.26M | $136.60M | $130.70M | $112.54M | $118.15M | $126.19M | $127.02M | $82.55M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $32.07M | $32.07M | $27.89M | $- | $20.70M | $- | $15.28M | $13.73M | $12.27M | $9.45M | $6.60M | $5.61M | $5.48M | $3.69M | $3.40M |
| Goodwill and Intangible Assets | $32.07M | $32.07M | $27.89M | $24.78M | $20.70M | $15.10M | $15.28M | $13.73M | $12.27M | $9.45M | $6.60M | $5.61M | $5.48M | $3.69M | $3.40M |
| Long Term Investments | $50.50M | $50.50M | $49.20M | $48.72M | $49.78M | $37.01M | $36.33M | $33.18M | $19.61M | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $-20.70M | $-15.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-260.20M | $-260.20M | $31.46M | $31.10M | $58.30M | $38.87M | $23.42M | $26.25M | $15.36M | $11.97M | $9.84M | $14.45M | $12.68M | $10.85M | $7.80M |
| Total Non-Current Assets | $260.20M | $260.20M | $313.60M | $284.22M | $270.44M | $212.25M | $207.37M | $207.42M | $183.83M | $152.13M | $128.98M | $138.21M | $144.36M | $141.56M | $93.75M |
| Other Assets | $6.17M | $6.17M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $975.33M | $975.33M | $1.30B | $1.33B | $1.52B | $1.65B | $1.75B | $1.88B | $1.97B | $2.25B | $2.19B | $605.36M | $573.51M | $293.52M | $324.44M |
| Account Payables | $63.05M | $63.05M | $53.69M | $57.42M | $55.77M | $38.91M | $36.17M | $28.45M | $34.07M | $26.59M | $37.94M | $61.83M | $49.95M | $22.41M | $11.90M |
| Short Term Debt | $- | $- | $111.94M | $53.05M | $40.13M | $47.23M | $46.99M | $47.42M | $75.17M | $68.56M | $67.36M | $77.23M | $34.88M | $34.58M | $- |
| Tax Payables | $- | $- | $- | $- | $2.58M | $- | $- | $- | $1.67M | $- | $- | $- | $4.63M | $- | $929.00K |
| Deferred Revenue | $- | $- | $26.00M | $8.69M | $11.96M | $12.64M | $9.72M | $11.40M | $8.42M | $6.13M | $5.62M | $12.85M | $18.19M | $12.59M | $8.87M |
| Other Current Liabilities | $326.82M | $326.82M | $158.48M | $130.35M | $154.65M | $121.45M | $112.47M | $140.79M | $109.52M | $263.58M | $101.32M | $89.52M | $105.08M | $119.77M | $54.95M |
| Total Current Liabilities | $389.87M | $389.87M | $350.10M | $249.52M | $265.09M | $220.23M | $205.35M | $228.06M | $228.84M | $364.86M | $212.24M | $241.43M | $212.74M | $189.35M | $67.77M |
| Long Term Debt | $- | $- | $49.16M | $30.13M | $33.87M | $32.69M | $40.34M | $45.71M | $48.51M | $46.01M | $25.36M | $27.81M | $32.77M | $39.30M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $9.18M | $8.89M | $8.61M | $8.35M | $8.10M | $7.80M | $-48.51M | $-46.01M | $-25.36M | $2.19B | $2.07B | $1.61B | $1.32B |
| Total Non-Current Liabilities | $- | $- | $58.34M | $39.03M | $42.48M | $41.05M | $48.43M | $53.51M | $48.51M | $46.01M | $25.36M | $27.81M | $2.14B | $1.68B | $1.32B |
| Other Liabilities | $27.34M | $27.34M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $426.97M | $426.97M | $408.44M | $288.54M | $307.57M | $261.28M | $253.79M | $281.57M | $277.35M | $410.87M | $237.60M | $269.24M | $2.35B | $1.87B | $1.39B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $61.00K | $61.00K | $61.00K | $61.00K | $61.00K | $60.00K | $59.00K | $59.00K | $59.00K | $59.00K | $59.00K | $48.00K | $17.00K | $- | $- |
| Retained Earnings | $-6.25B | $-6.25B | $-5.85B | $-5.61B | $-5.44B | $-5.27B | $-5.14B | $-5.05B | $-4.94B | $-4.84B | $-4.79B | $-1.96B | $-1.84B | $-1.71B | $-1.17B |
| Accumulated Other Comprehensive Income Loss | $- | $- | $20.73M | $-64.34M | $-69.09M | $-44.78M | $-49.92M | $-21.14M | $-24.70M | $18.23M | $92.28M | $77.30M | $69.21M | $134.60M | $112.26M |
| Other Total Stockholders Equity | $6.79B | $6.79B | $6.74B | $6.71B | $6.64B | $6.66B | $6.63B | $6.65B | $6.63B | $6.68B | $6.75B | $2.22B | $-3.58M | $-4.18M | $-8.36M |
| Total Stockholders Equity | $546.12M | $546.12M | $891.95M | $1.04B | $1.21B | $1.38B | $1.49B | $1.59B | $1.69B | $1.84B | $1.96B | $336.12M | $-1.78B | $-1.58B | $-1.06B |
| Total Equity | $548.36M | $548.36M | $894.92M | $1.04B | $1.21B | $1.39B | $1.49B | $1.60B | $1.69B | $1.84B | $1.96B | $336.12M | $-1.78B | $-1.58B | $-1.06B |
| Total Liabilities and Stockholders Equity | $975.33M | $975.33M | $1.30B | $1.33B | $1.52B | $1.65B | $1.75B | $1.88B | $1.97B | $2.25B | $2.19B | $605.36M | $573.51M | $293.52M | $324.44M |
| Minority Interest | $2.23M | $2.23M | $2.98M | $3.94M | $4.46M | $7.04M | $8.21M | $8.54M | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $975.33M | $975.33M | $1.30B | $1.33B | $1.52B | $1.65B | $1.75B | $1.88B | $1.97B | $2.25B | $2.19B | $605.36M | $573.51M | $293.52M | $324.44M |
| Total Investments | $55.67M | $55.67M | $194.33M | $288.53M | $201.22M | $224.40M | $178.53M | $351.79M | $159.90M | $233.53M | $47.72M | $103.02M | $122.22M | $- | $38.60M |
| Total Debt | $- | $- | $161.10M | $83.19M | $73.99M | $79.93M | $87.33M | $93.13M | $123.68M | $114.57M | $92.72M | $105.04M | $67.64M | $73.88M | $- |
| Net Debt | $-176.27M | $-176.27M | $-166.45M | $-236.11M | $-565.05M | $-735.21M | $-979.49M | $-975.87M | $-1.25B | $-1.52B | $-1.75B | $-75.84M | $-72.31M | $68.49M | $-62.13M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-810.63M | $-502.60M | $-3.07B | $-676.03M | $-464.99M |
| Depreciation and Amortization | $77.42M | $63.09M | $53.20M | $46.59M | $27.86M |
| Deferred Income Tax | $- | $31.33M | $2.83B | $360.22M | $-6.49M |
| Stock Based Compensation | $17.49M | $54.14M | $29.95M | $35.88M | $29.64M |
| Change in Working Capital | $73.89M | $-151.67M | $-124.57M | $26.96M | $-20.60M |
| Accounts Receivables | $-10.57M | $-153.94M | $-95.72M | $-48.15M | $-27.41M |
| Inventory | $-6.82M | $-10.63M | $-7.08M | $3.72M | $-8.85M |
| Accounts Payables | $13.73M | $23.58M | $-9.07M | $26.63M | $2.94M |
| Other Working Capital | $77.56M | $-10.67M | $-12.71M | $44.76M | $12.72M |
| Other Non Cash Items | $181.62M | $-18.43M | $-24.79M | $9.42M | $233.56M |
| Net Cash Provided by Operating Activities | $-460.20M | $-524.14M | $-300.90M | $-196.96M | $-201.02M |
| Investments in Property Plant and Equipment | $-82.14M | $-85.89M | $-50.03M | $-25.58M | $-47.42M |
| Acquisitions Net | $- | $2.00M | $-13.37M | $679.00K | $3.52M |
| Purchases of Investments | $-1.24B | $-2.10B | $-1.73B | $-479.10M | $-895.14M |
| Sales Maturities of Investments | $1.24B | $2.06B | $1.70B | $396.42M | $1.12B |
| Other Investing Activities | $3.00M | $-10.57M | $13.08M | $10.78M | $-6.07M |
| Net Cash Used for Investing Activities | $-87.83M | $-136.28M | $-84.65M | $-96.81M | $171.49M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $1.68B | $18.00K | $- |
| Common Stock Repurchased | $- | $- | $-4.10M | $-54.48M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $71.37M | $-58.41M | $1.74B | $371.73M | $49.40M |
| Net Cash Used Provided by Financing Activities | $71.37M | $-58.41M | $1.74B | $371.73M | $49.40M |
| Effect of Forex Changes on Cash | $13.89M | $-17.90M | $-123.15M | $-139.00K | $223.00K |
| Net Change in Cash | $-462.78M | $-736.72M | $1.24B | $77.83M | $20.10M |
| Cash at End of Period | $176.27M | $639.04M | $1.38B | $139.95M | $62.13M |
| Cash at Beginning of Period | $639.04M | $1.38B | $139.95M | $62.13M | $42.03M |
| Operating Cash Flow | $-460.20M | $-524.14M | $-300.90M | $-196.96M | $-201.02M |
| Capital Expenditure | $-82.14M | $-85.89M | $-50.03M | $-25.58M | $-47.42M |
| Free Cash Flow | $-542.34M | $-610.04M | $-350.92M | $-222.54M | $-248.44M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | December 31, 2021 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $- | $- | $- | $- | $- | $3.00B | $-48.00M | $-2.83B | $- | $- | $-274.07M | $- | $- |
| Depreciation and Amortization | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-129.18M | $- | $- |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non Cash Items | $- | $- | $- | $- | $- | $-3.45B | $48.00M | $2.83B | $- | $- | $274.07M | $- | $- |
| Net Cash Provided by Operating Activities | $- | $- | $- | $- | $- | $-452.61M | $- | $- | $-71.53M | $-67.78M | $-129.18M | $-59.15M | $-35.77M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $-67.94M | $- | $- | $-5.55M | $-8.17M | $-17.42M | $-3.18M | $-11.03M |
| Acquisitions Net | $- | $- | $- | $- | $- | $-1.80M | $- | $- | $1.80M | $-37.00K | $- | $707.00K | $-3.31M |
| Purchases of Investments | $- | $- | $- | $- | $- | $223.02M | $- | $- | $-251.91M | $-222.25M | $- | $-164.70M | $-99.28M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $-265.75M | $- | $- | $265.75M | $100.26M | $- | $154.29M | $168.73M |
| Other Investing Activities | $- | $- | $- | $- | $- | $-32.09M | $- | $- | $-1.80M | $10.97M | $39.84M | $-4.29M | $2.69M |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $-144.56M | $- | $- | $8.29M | $-119.23M | $22.42M | $-17.54M | $64.42M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $-162.18M | $- | $- | $103.77M | $321.69M | $50.04M | $18.54M | $- |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $- | $- | $-162.18M | $- | $- | $103.77M | $321.69M | $50.04M | $18.54M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $-405.00K | $- | $- | $405.00K | $-123.00K | $-16.00K | $12.00K | $92.00K |
| Net Change in Cash | $- | $- | $- | $- | $- | $-759.76M | $- | $- | $40.93M | $134.57M | $-56.74M | $-58.14M | $28.74M |
| Cash at End of Period | $- | $- | $- | $- | $48.93M | $639.04M | $- | $- | $180.89M | $139.95M | $-56.74M | $3.98M | $62.13M |
| Cash at Beginning of Period | $- | $- | $- | $- | $48.93M | $1.40B | $- | $- | $139.95M | $5.39M | $- | $62.13M | $33.38M |
| Operating Cash Flow | $- | $- | $- | $- | $- | $-452.61M | $- | $- | $-71.53M | $-67.78M | $-129.18M | $-59.15M | $-35.77M |
| Capital Expenditure | $- | $- | $- | $- | $- | $-67.94M | $- | $- | $-5.55M | $-8.17M | $-17.42M | $-3.18M | $-11.03M |
| Free Cash Flow | $- | $- | $- | $- | $- | $-520.55M | $- | $- | $-77.08M | $-75.94M | $-146.60M | $-62.34M | $-46.80M |
Genetron Holdings Dividends
Explore Genetron Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Genetron Holdings News
Read the latest news about Genetron Holdings, including recent articles, headlines, and updates.
Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model
Patented directed graph model delivers immediate, low-risk visibility of your identities and access in days, not months GOLD COAST, Australia & SEATTLE–(BUSINESS WIRE)–Gathid (ASX: GTH) today announced the debut of its new approach to identity and access governance. Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented … The post Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model appe...
Genetron Health Announces Completion of Going Private
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger … The post Genetron Health Announces Completion of Going Private appeared first on Headlines of Toda...
Genetron Health Announces Completion of Going Private Transaction
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.
Genetron Health Announces Shareholders' Approval of Merger Agreement
BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the “Merger”), the plan of merger (the “Plan of Merger”) required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.
Genetron Health to Hold Extraordinary General Meeting of Shareholders
BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”) and the transactions contemplated thereby, including the Merger (as defined below).
Genetron stock rallies on CEO-led deal to go private
Genetron Holdings has announced it will go private through an acquisition by a group of investors led by its co-founder and CEO Sizhen Wang and CICC Healthcare Investment Fund which values the Chinese precision oncology platform at US$126 million. The company's US-listed American Depository Shares (ADSs) jumped 27% in early Thursday trading to $1.1950.
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement and subject to the terms and conditions thereof, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity and becoming a wholly-owned subsidiary of Parent (the “Merger”), in a transaction implying an equity value of the Company of approximately US$126.0 million.
Genetron Health Announces Receipt of Notification from
BEIJING, May 23, 2023 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications […]...
Genetron Health Announces Receipt of a Preliminary
BEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that its Board of Directors (the “Board”) has received a preliminary non-binding proposal […]...
Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2022 Results - Earnings Call Transcript
Genetron Holdings Limited (NASDAQ:GTH ) Q1 2022 Earnings Conference Call June 2, 2022 8:30 AM ET Company Participants Evan Xu - Chief Financial Officer Sizhen Wang - Co-Founder, Chairman & Chief Executive Officer Conference Call Participants Yang Huang - Credit Suisse Operator Good morning, and thank you for standing by. Welcome to the First Quarter 2022 Genetron Health Earnings Conference Call.
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open.
Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications
SAN DIEGO--(BUSINESS WIRE)-- #3Dgenomics--Arima Genomics closes $7M series B financing to support continued growth of 3D genomics portfolio for research and translational applications.
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
BEIJING, March 09, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2021 on March 29, 2022 before the US market open.
Genetron Health to Participate in Upcoming Investor Conferences
BEIJING, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in two upcoming virtual investor conferences.
Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
BEIJING, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a partnership with IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics.
Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has partnered with a consortium of 14 top Chinese hospitals to release 13 key research findings at the ESMO 2021 Congress, hosted by the European Society for Medical Oncology. The findings focus on the exploration of genomics amongst the Chinese population, and provide important insights for clinical pathology classification, targeted therapy and immunotherapy strategies, and the clinical management of hereditary colorectal cancer.
Genetron Added to FTSE Russell Global Equity Index Series
BEIJING, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that Genetron will be added to the below FTSE Global Equity Index Series ("GEIS"), following FTSE's most recent quarterly review. These inclusions will become effective after the market close on Friday, September 17, 2021:
Genetron Health's Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021
BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021. Awarded by the Gertrud Reemtsma Foundation through the Max Planck Society, the prize is one of the most prominent awards in neuroscience and recognizes individuals who have made outstanding and original contributions to the understanding of neurobiology and neurological disease. The ceremony took place at the Max-Planck-Institute in Cologne, Germany, on August 26.
Genetron Health Reports Second Quarter 2021 Unaudited Financial Results
BEIJING, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the second quarter ended June 30, 2021.
Genetron Health to Host Calls Following Earnings and Participate in an Upcoming Investor Conference
BEIJING, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host calls with various brokers following second quarter earnings and participate in an investor conference with Wells Fargo.
Genetron Health Tops NCCL's External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks
BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories' (“NCCL”) first nationwide, external quality assessment (“EQA”) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation “Outstanding Laboratory” and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation.
Genetron Health Partners with Guizhou Province's Dafang County to Lead Liver Cancer Early Screening Project
BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Province's Dafang County authorities to lead the “Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project”. Backed by the Central Committee of the Chinese Peasants and Workers Democratic Party and guided by China's National Cancer Center, this project is a collective effort that will be carried out by the Dafang County Health Bureau, the People's Hospital of Dafang, and Genetron Health.
AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China
BEIJING, July 26, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that its AYVAKIT® (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (“CStone”, HKEX: 2616) has entered the priority review and approval process under the National Medical Products Administration (NMPA) in China.
Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test
The CE Mark and comparative data highlight the Company's capability in providing high quality and consistent testing products The CE Mark and comparative data highlight the Company's capability in providing high quality and consistent testing products
Genetron Health Enters into Platform Partnership with World Economic Forum
BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform.
Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
BEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GTH.